LY3298176 · GLP-1/GIP Dual Agonist
Dual GLP-1/GIP receptor agonist. Research-grade tirzepatide compound.
Tirzepatide (LY3298176) is a synthetic GIP/GLP-1 dual receptor agonist. SURMOUNT-1 phase 3 data (NEJM, 2022) demonstrated 20.9% mean body weight reduction vs 3.1% placebo over 72 weeks, establishing it as a benchmark for dual incretin research.
Store lyophilized at -20°C for 12–24 months. Reconstituted: refrigerate at 2–8°C, use within 4–6 weeks.